Recombinant herpes simplex virus, and preparation method therefor and use thereof

By inserting shRNA that interferes with DPD into the recombinant herpes simplex virus, the expression of DPD genes is reduced, and the killing ability of CD/5-FC to glioma cells is improved, and the problem that interferes with TSPO genes in the prior art cannot directly enhance killing function is solved. , achieving more efficient glioma cell killing and chemotherapy efficiency.

WO2024244306A1PCT designated stage expired Publication Date: 2024-12-05ZHONGYI (SUZHOU) BIOPHARMACEUTICAL CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/130345
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-30
Filing Date
2023-11-08
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

When treating brain glioma, the inserted TSPO gene can interfere with glioma metabolism, but it cannot directly enhance the killing function of CD/5-FC, resulting in the killing efficiency of glioma cells. Not high enough.

Method used

Inserting shRNA that interferes with DPD into HSV-CD reduces the DPD gene expression level, thereby improving the killing ability of CD/5-FC to glioma cells and enhancing the utilization rate and half-life of chemotherapeutic drug 5-FU.

Benefits of technology

Effectively reduce the metabolism and invasion ability of glioma cells, improve chemotherapy efficiency, increase the killing effect of chemotherapy drugs on glioma cells, and prolong the action time of chemotherapy drugs in cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023130345_05122024_PF_FP_ABST
    Figure CN2023130345_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to the technical field of genetic engineering. Disclosed are a recombinant herpes simplex virus, and a preparation method therefor and the use thereof. The recombinant herpes simplex virus comprises a vector and a nucleotide sequence for reducing the expression level of a DPD gene, wherein the vector is a herpes simplex virus which lacks an ICP47 coding gene and contains a CD gene, and the insertion site of the nucleotide sequence for reducing the expression level of the DPD gene is the position on the vector at which the ICP47 coding gene is deleted. The recombinant herpes simplex virus inserts shRNA interfering with DPD into HSV-CD, thereby improving the killing ability of CD / 5-FC on glioma cells while interfering with the metabolism of the glioma cells.
Need to check novelty before this filing date? Find Prior Art

Description

A recombinant herpes simplex virus and its preparation method and application Technical Field

[0001] The present invention relates to the technical field of genetic engineering, and in particular to a recombinant herpes simplex virus and a preparation method and application thereof. Background Art

[0002] Oncolytic viruses have been used for cancer treatment in a variety of preclinical and clinical studies. Oncolytic viruses achieve tumor-killing effects by deleting specific genes in the viral genome, thereby giving the oncolytic virus the ability to selectively replicate and amplify in tumor cells. At the same time, the modified oncolytic virus cannot replicate in normal cells and therefore has a higher safety profile. Herpes simplex virus type 1 (HSV-1) is one of the most widely used oncolytic viruses in clinical practice.

[0003] Currently, there are studies on the use of genetic engineering to modify wild-type HSV-1, delete specific genes, and use it as a gene expression vector for human gene therapy. The therapeutic gene is expressed while the tumor is lysed to cooperate with the oncolytic virus therapy. Two expression frameworks are inserted on the basis of the modification of wild-type HSV-1. One is the ability to express cytosine deaminase (CD) in tumor cells. CD can convert exogenous non-toxic 5-FC (prodrug 5-fluorocytosine) into the chemotherapy drug 5-FU (5-fluorouracil) in the cells, interfering with the DNA synthesis of tumor cells. The other is the insertion of shRNA that interferes with the TSPO gene to reduce its expression. After triple modification, the HSV-CD-shTSPO oncolytic virus is constructed.

[0004] The above-mentioned recombinant herpes simplex virus can effectively reduce the growth rate of brain glioma, provide sufficient time for HSV-1 oncolytic virus to kill brain glioma cells, improve the killing efficiency of brain glioma, and have few side effects after use; however, the shRNA that interferes with the TSPO gene inserted in this technology, although it plays a role in interfering with the metabolism of glioma cells, has no direct relationship with the CD gene inserted in the virus, and it cannot directly enhance the killing function of CD / 5-FC.

[0005] Summary of the Invention

[0006] In response to the above problems, the first object of the present invention is to provide a recombinant herpes simplex virus, which inserts shRNA that interferes with DPD into HSV-CD, thereby interfering with glioma cell metabolism while improving the killing ability of CD / 5-FC on glioma cells.

[0007] The second object of the present invention is to provide a method for preparing the above-mentioned recombinant herpes simplex virus.

[0008] The third object of the present invention is to provide a use of a recombinant herpes simplex virus in the preparation of a medicament for treating brain glioma.

[0009] The first technical solution adopted by the present invention is: a recombinant herpes simplex virus, wherein the recombinant herpes simplex virus comprises a vector and a nucleotide sequence for reducing the expression level of the DPD gene;

[0010] The vector is a herpes simplex virus that is missing the gene encoding ICP47 and contains the CD gene, and the insertion site of the nucleotide sequence for reducing the expression level of the DPD gene is the position of the gene encoding ICP47 missing on the vector;

[0011] The nucleotide sequence for reducing the expression level of the DPD gene is shown in SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3 or SEQ ID No: 4.

[0012] Preferably, the insertion site of the CD gene in the vector is the site where the gene encoding ICP34.5 is deleted.

[0013] Preferably, the DPD gene has a nucleotide sequence as shown in SEQ ID No: 5.

[0014] Preferably, the CD gene has the nucleotide sequence shown in SEQ ID No: 6.

[0015] Preferably, the carrier is obtained by:

[0016] The gene encoding ICP34.5 in the herpes simplex virus is knocked out, and the CD gene is inserted at the position of the gene encoding ICP34.5 knocked out, thereby obtaining a herpes simplex virus containing the CD gene;

[0017] The gene encoding ICP47 in the herpes simplex virus containing the CD gene is knocked out to obtain a vector.

[0018] The second technical solution adopted by the present invention is: a method for preparing the recombinant herpes simplex virus described in the first technical solution, comprising the following steps:

[0019] The gene encoding ICP47 in a herpes simplex virus containing the CD gene is knocked out to obtain a vector; a nucleotide sequence for reducing the expression level of the DPD gene is inserted into the vector; the insertion site of the nucleotide sequence for reducing the expression level of the DPD gene is the position on the vector where the gene encoding ICP47 is knocked out;

[0020] The nucleotide sequence for reducing the expression level of the DPD gene is shown in SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3 or SEQ ID No: 4.

[0021] Preferably, the herpes simplex virus containing the CD gene is obtained by the following method:

[0022] The gene encoding ICP34.5 in the herpes simplex virus is knocked out, and the CD gene is inserted at the position of the knocked-out gene encoding ICP34.5, thereby obtaining a herpes simplex virus containing the CD gene.

[0023] Preferably, the method for preparing a recombinant herpes simplex virus further comprises:

[0024] The CD gene was synthesized and cloned into the pSP72△ICP34.5CMVWPRE vector using Hind III and Xho I to obtain pSP72△ICP34.5CMVCDWPRE; pSP72△ICP34.5CMVCDWPRE and HSV-1△ICP34.5CMVEGFP were co-transfected into BHK cells, and viral plaques that did not express green fluorescence indicated that the gene EGFP in the original virus was replaced by the CD gene recombination. The HSV-1△ICP34.5CMVCDWPRE viral vector was purified and grown, and the full-length DNA of the vector was extracted to obtain herpes simplex virus containing the CD gene.

[0025] The third technical solution adopted by the present invention is: use of the recombinant herpes simplex virus described in the first technical solution or the recombinant herpes simplex virus prepared by the method described in the second technical solution in the preparation of a drug for treating brain glioma.

[0026] Beneficial effects of the above technical solution:

[0027] (1) The present invention inserts shRNA that interferes with DPD into HSV-CD to construct HSV-CD-shDPD oncolytic virus (i.e., recombinant herpes simplex virus). The recombinant herpes simplex virus effectively reduces glioma metabolism, invasion and migration, and at the same time improves the utilization rate of the inserted CD gene for the prodrug 5-FC, increases the half-life of 5-FU converted by the CD gene and the chemotherapy efficiency in glioma cells, that is, simultaneously improves the utilization rate of exogenous drugs, increases the half-life of chemotherapy drugs and the chemotherapy efficiency in glioma cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 shows the relationship between different pathological grades of glioma and DPD expression;

[0029] Figure 2 is a graph showing the relationship between DPD expression and prognosis in primary glioma;

[0030] FIG3 is a graph showing the relationship between DPD expression and prognosis in recurrent glioma;

[0031] Figure 4 is a schematic diagram of immunohistochemical detection of DPD expression in brain glioma pathological tissue, where Low grade refers to low grade and High grade refers to high grade;

[0032] FIG5 is a graph showing the interference efficiency of different shRNAs interfering with DPD;

[0033] FIG6 is a diagram showing the effect of interfering with DPD expression in glioma cells U251 to inhibit cell invasion and migration;

[0034] FIG7 is a diagram showing the effect of interfering with DPD expression in glioma cells and enhancing the cell-killing ability of 5-FU;

[0035] Figure 8 is a comparison of the utilization rates of 5-FC by sh-DPD-1#, sh-DPD-3#, and sh-TSPO. DETAILED DESCRIPTION

[0036] The present invention is further described below through specific embodiments. It should be pointed out that for ordinary technicians in this field, several modifications and improvements can be made without departing from the principles of the present invention, and these should also be regarded as falling within the scope of protection of the present invention.

[0037] DPD (dihydropyrimidine dehydrogenase) is the initiating and rate-limiting enzyme of 5-FU (5-fluorouracil) metabolism in the body. It can convert 5-FU into non-toxic dihydrofluorouracil in cells and is an inhibitory enzyme of the CD (cytosine deaminase) / 5-FC system. The DPD gene (DPYD) is not only involved in the metabolic process but also in the tumor EMT process. The inventors of the present invention conducted a bioinformatics analysis based on the Chinese Glioma Genome Atlas (CGGA) database to find the relationship between DPD (dihydropyrimidine dehydrogenase) expression and glioma. As shown in Figure 1, the higher the pathological grade of glioma (grade II, III to IV), the higher the DPD expression; as shown in Figures 2 and 3, in primary glioma and recurrent glioma, the higher the DPD expression, the poorer the prognosis of glioma; that is, DPD (dihydropyrimidine dehydrogenase) is generally highly expressed in brain glioma pathological tissue, and the higher the pathological grade, the higher the DPD expression; in vitro interference with DPD expression in glioma cells not only inhibits the invasion and migration of glioma cells, but also enhances the ability of 5-FU to kill glioma cells.

[0038] Based on the above bioinformatics analysis results, immunohistochemistry was used to analyze the expression of DPD in low-grade (II) and high-grade (III or IV) pathological tissues. As shown in Figure 4, it was found that DPD expression was higher in high-grade than in low-grade, further verifying the above analysis results.

[0039] Based on the above analysis, the present invention provides a recombinant herpes simplex virus, which comprises a vector and a nucleotide sequence for reducing the expression level of the DPD gene (i.e., shRNA that interferes with DPD); the vector is a herpes simplex virus that lacks the gene encoding ICP47 and contains the CD gene, and the insertion site of the nucleotide sequence for reducing the expression level of the DPD gene is the position on the vector where the gene encoding ICP47 is deleted;

[0040] Wherein, the nucleotide sequence for reducing the expression level of the DPD gene is as shown in SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3 or SEQ ID No: 4; preferably the nucleotide sequence as shown in SEQ ID No: 1 or SEQ ID No: 3; the insertion site of the CD gene in the herpes simplex virus that lacks the gene encoding ICP47 and contains the CD gene is at the site where the gene encoding ICP34.5 is lacking.

[0041] In the present invention, the gene encoding ICP34.5 and the gene encoding ICP47 are both well known to those skilled in the art and can be found by logging into relevant databases. For example, the relevant nucleotide sequences can be found by logging into the GenBank database. These are conventional technical means possessed by those skilled in the art and will not be elaborated herein.

[0042] The DPD gene has a nucleotide sequence as shown in SEQ ID No: 5.

[0043] The CD gene has a nucleotide sequence as shown in SEQ ID No: 6;

[0044] The prodrug 5-fluorocytosine (5-FC) has no effect on cells; 5-FU, obtained by deamination of 5-FC, has a killing effect on both normal cells and tumor cells. This process can be catalyzed by cytosine deaminase (CD), which is lacking in the human body. Cytosine deaminase (the expression product of the CD gene) can convert the originally non-toxic prodrug 5-FC into the cytotoxic chemotherapy drug 5-FU.

[0045] In the present invention, there is no particular limitation on the type of the herpes simplex virus, which can be a conventional choice in the art. However, in order to better achieve the purpose of stable expression of cytokines, the herpes simplex virus is preferably herpes simplex virus type I. The present invention also does not particularly limit the source of the herpes simplex virus, which can be obtained through conventional commercial purchase or by laboratory isolation.

[0046] On the other hand, the present invention also provides a method for preparing a recombinant herpes simplex virus, comprising: knocking out the gene encoding ICP47 in a herpes simplex virus containing the CD gene, thereby obtaining a vector; inserting a nucleotide sequence for reducing the expression level of the DPD gene into the vector; the insertion site of the nucleotide sequence for reducing the expression level of the DPD gene is the position on the vector where the gene encoding ICP47 was knocked out.

[0047] Among them, herpes simplex virus containing CD gene is obtained by the following means:

[0048] The gene encoding ICP34.5 in the herpes simplex virus is knocked out, and the CD gene is inserted at the position of the knocked-out gene encoding ICP34.5, thereby obtaining a herpes simplex virus containing the CD gene.

[0049] The genes encoding ICP34.5 and ICP47 can be knocked out using various conventional methods in the art, which are not particularly limited in the present invention. For example, they can be knocked out by homologous recombination, site-specific knockout, or CRISPY. Those skilled in the art, with an understanding of the objectives of the present invention and the viral vectors used in the present invention, can achieve knockout of the above genes using conventional techniques.

[0050] The insertion of the nucleotide sequence for reducing the expression level of the DPD gene and the CD gene can also be carried out by various conventional methods in the art. The insertion method can be to directly insert the target sequence into the selected insertion site, for example, by CRISPY, or by replacing part of the base sequence by homologous recombination to insert the target sequence.

[0051] The preparation of recombinant herpes simplex virus includes, for example:

[0052] (1) Synthesize the CD gene and clone it into the pSP72ΔICP34.5CMVWPRE vector using Hind III and Xho I (insert the HSV-1 DNA fragment containing the ICP34.5 gene into the BglII site of the plasmid pSP72, and delete the NotI fragment encoding the ICP34.5 gene after restriction endonuclease with NotI to obtain pSP72ΔICP34.5; control the IE promoter of human CMV virus and add WPRE (Woodchuck hepatitis post-regulation element) to obtain the pSP72ΔICP34.5CMVWPRE vector) to obtain pSP72ΔICP34.5CMVCDWPRE; pSP72ΔICP34.5 CMVCDWPRE and HSV-1△ICP34.5CMVEGFP (ICP34.5 gene was deleted from wild-type HSV-1 to obtain HSV-1△ICP34.5; the marker gene EGFP expressing green fluorescent protein was controlled by the IE promoter of human CMV virus and co-cloned into HSV-1△ICP34.5 to obtain HSV-1△ICP34.5CMVEGFP) were co-transfected into BHK cells. Viral plaques that did not express green fluorescence indicated that the gene EGFP in the original virus was replaced by the CD gene recombination. The HSV-1△ICP34.5CMVCDWPRE viral vector was purified and grown, and the full-length DNA of the vector was extracted to obtain herpes simplex virus containing the CD gene.

[0053] (2) artificially synthesizing the nucleotide sequence shown in SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3 or SEQ ID No: 4 (the artificial synthesis is completed by the entrusted Hunan Yada Fenghui New Materials Co., Ltd.), thereby obtaining an artificially synthesized first nucleotide sequence, second nucleotide sequence, third nucleotide sequence or fourth nucleotide sequence; knocking out the ICP47 gene of the herpes simplex virus containing the CD gene, and inserting the artificially synthesized first nucleotide sequence, second nucleotide sequence, third nucleotide sequence or fourth nucleotide sequence at the position of the knocked-out ICP47 gene, thereby obtaining a recombinant herpes simplex virus;

[0054] (3) Perform enzyme digestion verification and sequence verification of the recombinant herpes simplex virus (sequencing verification was entrusted to Beijing Tianyi Huiyuan Biotechnology Co., Ltd.) to confirm that the reading frame of the recombinant herpes simplex virus is correct, and select the virus in which the nucleotide sequence for reducing the expression level of the DPD gene is correctly inserted into the herpes simplex virus containing the CD gene as the recombinant herpes simplex virus.

[0055] The recombinant herpes simplex virus disclosed in the present invention can be used for preparing medicine for treating brain glioma.

[0056] The present invention will be described in detail below through examples.

[0057] Example 1

[0058] Preparation of herpes simplex virus containing CD gene:

[0059] According to the method described in the patent application with application number 2004100064921 and authorization publication number CN1283803C, the ICP34.5 gene of the wild-type HSV-1 virus (GenBank number of its gene sequence: NC_001806) was knocked out, and the CD gene was inserted at the position of the knocked-out ICP34.5 gene of the HSV-1 virus, thereby obtaining a herpes simplex virus containing the CD gene (i.e., HSV-CD).

[0060] Example 2

[0061] The ICP47 gene of the herpes simplex virus containing the CD gene was knocked out (the knockout method was the same as in Example 1), and a nucleotide sequence (DPYD-1#) as shown in SEQ ID No: 1 (GCAATTTGCTACTGAGGTATT) for reducing the expression level of the DPD gene was inserted at the position of the knockout ICP47 gene; a recombinant viral vector was then constructed with the plasmid vector; the successfully constructed recombinant viral vector was cultured on Vero cells at 37°C and 5% CO 2 The cells were proliferated under the following conditions with a multiplicity of infection of 0.1. After harvest, cell debris was removed using a 0.65 μm filter and then purified by high-speed centrifugation at 13,000 rpm to obtain a virus suspension with a titer of 1×108 pfu / mL, thereby obtaining the recombinant herpes simplex virus HSV-CD-shDPD-1# (i.e., sh-DPD-1#), which was used for subsequent cell experiments.

[0062] Example 3

[0063] The ICP47 gene of the herpes simplex virus containing the CD gene was knocked out (the knockout method was the same as in Example 1), and a nucleotide sequence (DPYD-2#) as shown in SEQ ID No: 2 (GCCGTATGATGTAGTGAATTT) for reducing the expression level of the DPD gene was inserted at the position of the knocked-out ICP47 gene; a recombinant viral vector was then constructed with the plasmid vector; the successfully constructed recombinant viral vector was cultured on Vero cells at 37°C and 5% CO 2The cells were proliferated under the following conditions with a multiplicity of infection of 0.1. After harvest, cell debris was removed using a 0.65 μm filter and then purified by high-speed centrifugation at 13,000 rpm to obtain a virus suspension with a titer of 1×108 pfu / mL, thereby obtaining the recombinant herpes simplex virus HSV-CD-shDPD-2# (i.e., sh-DPD-2#), which was used for subsequent cell experiments.

[0064] Example 4

[0065] The ICP47 gene of the herpes simplex virus containing the CD gene was knocked out (the knockout method was the same as in Example 1), and a nucleotide sequence (DPYD-3#) as shown in SEQ ID No: 3 (GCTATACAGTTTGATCCAGAA) for reducing the expression level of the DPD gene was inserted at the position of the knockout ICP47 gene; a recombinant viral vector was then constructed with the plasmid vector; the successfully constructed recombinant viral vector was cultured on Vero cells at 37°C and 5% CO 2 The cells were proliferated under the following conditions with a multiplicity of infection of 0.1. After harvest, cell debris was removed using a 0.65 μm filter and then purified by high-speed centrifugation at 13,000 rpm to obtain a virus suspension with a titer of 1×108 pfu / mL, thereby obtaining the recombinant herpes simplex virus HSV-CD-shDPD-3# (i.e., sh-DPD-3#), which was used for subsequent cell experiments.

[0066] Example 5

[0067] The ICP47 gene of the herpes simplex virus containing the CD gene was knocked out (the knockout method was the same as in Example 1), and a nucleotide sequence (DPYD-4#) as shown in SEQ ID No: 4 (GCAAGTATAAGTTGTGCTTCC) for reducing the expression level of the DPD gene was inserted at the position of the knockout ICP47 gene; a recombinant viral vector was then constructed with the plasmid vector; the successfully constructed recombinant viral vector was cultured on Vero cells at 37°C and 5% CO 2 The cells were proliferated under the following conditions with a multiplicity of infection of 0.1. After harvest, cell debris was removed using a 0.65 μm filter and then purified by high-speed centrifugation at 13,000 rpm to obtain a virus suspension with a titer of 1×108 pfu / mL, thereby obtaining the recombinant herpes simplex virus HSV-CD-shDPD-4# (i.e., sh-DPD-4#), which was used for subsequent cell experiments.

[0068] Comparative Example 1

[0069] The recombinant herpes simplex virus was constructed according to the method in Example 2, except that only the ICP47 gene of the herpes simplex virus containing the CD gene was knocked out, and the nucleotide sequence for reducing the expression level of the DPD gene was not inserted, resulting in HSV-CD-shcon (i.e., sh-con).

[0070] Comparative Example 2

[0071] The recombinant herpes simplex virus was constructed according to the method in Example 2, except that the ICP47 gene of the herpes simplex virus containing the CD gene was knocked out, and a nucleotide sequence for reducing the expression level of the TSPO gene was inserted at the position of the knocked-out ICP47 gene to obtain the recombinant herpes simplex virus HSV-CD-sh-TSPO. The nucleotide sequence for reducing the expression level of the TSPO gene was:

[0072] TCACTCAACTACTGCGTATGTTCAAGAGACATACGCAGTAGTTGAGTGTTTTTT.

[0073] The DPYD-1#, DPYD-2#, DPYD-3#, DPYD-4#, CD gene and shTSPO in the present invention were synthesized by Hunan Yada Fenghui New Materials Co., Ltd.; Vero cells were purchased from ATCC with the product number CCL-81.

[0074] Test Example 1

[0075] The recombinant herpes simplex viruses in Example 2 (sh-DPD-1#), Example 3 (sh-DPD-2#), Example 4 (sh-DPD-3#), Example 5 (sh-DPD-4#) and Comparative Example 1 (sh-con) were transfected into glioma cells U251, and the transfection process (using 3000 transfection reagent, purchased from Thermo Fisher Scientific, the method is as follows: glioma cells U251 were seeded into 24-well plates and incubated at 37°C and 5% CO 2 After the cells adhered to the wall, the recombinant herpes simplex viruses constructed in the corresponding Examples 2-5 and Comparative Example 1 (infection multiplicity MOI = 0.01) were added to infect glioma cells U251, respectively, at 37°C and 5% CO 2After culturing for 24 hours, the cells were collected and Western blot was used to detect the expression of DPD protein in cells transfected with sh-DPD-1#, sh-DPD-2#, sh-DPD-3#, sh-DPD-4# and sh-con, thereby obtaining the interference efficiency of different nucleotide sequences for reducing the expression level of the DPD gene; among them, normal U251 cells (i.e., sh-con) not transfected with shRNA interfering with DPD were used as a control, and actin was used as a reference protein; the test results are shown in Figure 5. As shown in Figure 5, DPYD-1#, DPYD-2#, DPYD-3# and DPYD-4# can all effectively reduce the expression of the DPD gene, among which DPYD-1# and DPYD-3# have the best effect on reducing the expression of the DPD gene, that is, the efficiency of interfering with the expression of the DPD gene is higher.

[0076] Test Example 2

[0077] The recombinant herpes simplex viruses in Example 2 (sh-DPD-1#), Example 4 (sh-DPD-3#) and Comparative Example 1 (sh-con) were respectively transfected into glioma cells U251 (the transfection method used was the same as that in Test Example 1). After sh-DPD-1#, sh-DPD-3# and sh-con were transfected into glioma cells U251, the cell invasion and migration abilities were detected by Transwell assay. The test results are shown in FIG6 . As can be seen from FIG6 , after the expression of DPYD-1# and DPYD-3# (i.e., shRNA interfering with DPD), the invasion and migration abilities of glioma cells were reduced, and the effect of DPYD-1# (i.e., sh-DPD-1#) interfering with DPD expression was better than that of DPYD-3# (i.e., sh-DPD-3#). The better the effect of interfering with DPD expression, the more obvious the effect of inhibiting cell invasion and migration.

[0078] After DPYD-1# and DPYD-3# interfered with DPD expression, the tumor cell activity was detected by CCK8 to detect the ability of 5-FU to kill cells. The test results are shown in Figure 7. As can be seen from Figure 7, when no 5-FU was added (i.e., -5-FU in Figure 7), the activity of glioma cells decreased after DPD interference; when 5-FU was added (i.e., +5-FU in Figure 7), 5-FU (5-FU concentration was 100umol / L) could effectively kill glioma cells, and the activity of glioma cells further decreased after adding 5-FU to cells with interfered DPD expression, and the effect of DPYD-1# (i.e., sh-DPD-1#) was better than that of DPYD-3# (i.e., sh-DPD-3#), which proved that after interfering with DPD expression, glioma cells were more sensitive to 5-FU, increasing the half-life of chemotherapy drugs and the chemotherapy efficiency in glioma cells.

[0079] Test Example 3

[0080] The recombinant herpes simplex viruses in Example 2 (sh-DPD-1#, i.e., HSV-CD-shDPD-1#), Example 4 (sh-DPD-3#, i.e., HSV-CD-shDPD-3#) and Comparative Example 2 (HSV-CD-sh-TSPO) were respectively transfected into glioma cells U251 (the transfection method used was the same as that in Test Example 1). After sh-DPD-1#, sh-DPD-3# and HSV-CD-sh-TSPO were transfected into glioma cells U251, DPYD-1# and DPYD-3# interfered with DPD expression, and the tumor cell activity was detected by CCK8 to detect the ability of 5-FU to kill cells. The test results are shown in Figure 8. As can be seen from Figure 8, without the addition of 5-FC ( That is, -5-FC in Figure 8 ), after interfering with DPD, the activity of glioma cells decreased, and the activity of glioma cells after interfering with DPD was lower than that after interfering with TSPO; when 5-FC (i.e., +5-FC in Figure 8 ) was added, 5-FC was deaminated and converted into 5-FU by cytosine deaminase (CD). 5-FU can effectively kill glioma cells, and compared with the activity of glioma cells after adding 5-FC in cells interfering with TSPO expression, the activity of glioma cells after adding 5-FC in cells interfering with DPD expression of the present invention further decreased, proving that the insertion of a nucleotide sequence for reducing the expression level of the DPD gene can effectively improve the utilization rate of the inserted CD gene for the prodrug 5-FC, that is, simultaneously improve the utilization rate of exogenous drugs.

[0081] In the above test example, the glioma cell line U251 was purchased from ATCC with the catalog number TX-1725.

[0082] Although the present invention has been disclosed above with reference to preferred embodiments, this is not intended to limit the present invention. Anyone familiar with this technology may make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.

Claims

1. A recombinant herpes simplex virus, It is characterized in that The recombinant herpes simplex virus comprises a vector and a nucleotide sequence for reducing the expression level of the DPD gene; The vector is a herpes simplex virus lacking the gene encoding ICP47 and containing the CD gene, and the insertion site of the nucleotide sequence for reducing the expression level of the DPD gene is the position of the gene encoding ICP47 lacking on the vector; The nucleotide sequence for reducing the expression level of the DPD gene is shown in SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3 or SEQ ID No:

4.

2. The recombinant herpes simplex virus according to claim 1, It is characterized in that The insertion site of the CD gene in the vector is the site where the ICP34.5 coding gene is deleted.

3. The recombinant herpes simplex virus according to claim 1, It is characterized in that The DPD gene has a nucleotide sequence as shown in SEQ ID No:

5.

4. The recombinant herpes simplex virus according to claim 1, It is characterized in that The CD gene has a nucleotide sequence as shown in SEQ ID No:

6.

5. The recombinant herpes simplex virus according to claim 1, It is characterized in that The carrier is obtained by the following method: The gene encoding ICP34.5 in the herpes simplex virus is knocked out, and the CD gene is inserted at the position of the knocked-out gene encoding ICP34.5, thereby obtaining a herpes simplex virus containing the CD gene; The gene encoding ICP47 in herpes simplex virus containing the CD gene is knocked out to obtain a vector.

6. A method for preparing the recombinant herpes simplex virus according to any one of claims 1 to 5, It is characterized in that The following steps are involved: The gene encoding ICP47 in the herpes simplex virus containing the CD gene is knocked out to obtain a vector; a nucleotide sequence for reducing the expression level of the DPD gene is inserted into the vector; the insertion site of the nucleotide sequence for reducing the expression level of the DPD gene is the position of the gene encoding ICP47 knocked out on the vector; The nucleotide sequence for reducing the expression level of the DPD gene is shown in SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3 or SEQ ID No:

4.

7. The method for preparing a recombinant herpes simplex virus according to claim 6, It is characterized in that The herpes simplex virus containing the CD gene is obtained by the following method: The gene encoding ICP34.5 in the herpes simplex virus is knocked out, and the CD gene is inserted at the position of the knocked-out gene encoding ICP34.5, thereby obtaining a herpes simplex virus containing the CD gene.

8. The method for preparing a recombinant herpes simplex virus according to claim 7, It is characterized in that The following steps are also included: The CD gene was synthesized and cloned into the pSP72△ICP34.5CMVWPRE vector using Hind III and Xho I to obtain pSP72△ICP34.5CMVCDWPRE; pSP72△ICP34.5CMVCDWPRE and HSV-1△ICP34.5CMVEGFP were co-transfected into BHK cells, and virus plaques that did not express green fluorescence indicated that the gene EGFP in the original virus was replaced by the CD gene recombination; the HSV-1△ICP34.5CMVCDWPRE virus vector was purified and grown, and the full-length DNA of the vector was extracted to obtain the herpes simplex virus containing the CD gene.

9. Use of the recombinant herpes simplex virus according to any one of claims 1 to 5 or the recombinant herpes simplex virus prepared by the method according to any one of claims 6 to 8 in the preparation of a medicament for treating brain glioma.

Citation Information

Patent Citations

  • Attenuated HSV-1 vector for gene therapy

    CN1283803C

  • Retroviral vector with mini-promoter cassette

    CN104884627A

  • Application of TSPO (Translocator Protein) in treatment of brain glioma and recombinant herpes simplex virus as well as preparation method and application of recombinant herpes simplex virus

    CN108004216A

  • Application of oncolytic virus in treatment on uveal melanoma, marker of treatment effect and detection reagent thereof

    CN111850126A

  • Recombinant herpes simplex virus as well as preparation method and application thereof

    CN116334010A